Navigation Links
Novelos Therapeutics To Present At The 15th Annual BIO CEO & Investor Conference On February 11
Date:2/4/2013

MADISON, Wis., Feb. 4, 2013 /PRNewswire/ -- Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that Harry S. Palmin, President and CEO of Novelos, will present a corporate update at the 15th Annual BIO CEO & Investor Conference on Monday, February 11, 2013.  Mr. Palmin is scheduled to present at 2pm ET in the Duke of Windsor Suite on the 4th floor.  The event will be held February 11-12 at The Waldorf Astoria in New York City.

A live webcast of the Novelos presentation may be accessed via www.novelos.com 
The webcast will be archived for 90 days following the presentation.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies.  Information about the conference is available at http://www.bio.org/events/conferences/bio-ceo-investor-conference

About Novelos Therapeutics, Inc.
We are a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer.  Our cancer-targeted compounds are selectively taken up and retained in cancer cells, including cancer stem cells, versus normal cells.  Thus, our therapeutic compounds appear to directly kill cancer cells while minimizing harm to normal cells.  This offers the potential for a paradigm shift in cancer therapy by providing efficacy versus all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse.  I-124-CLR1404 (LIGHT) is a small-molecule, broad-spectrum, cancer-targeted PET imaging agent.  We believe LIGHT has first-in-class potential and Phase 1-2 clinical trials are ongoing across 11 solid tumor indications.  I-131-CLR1404 (HOT) is a small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells.  We believe HOT also has first-in-class potential.  HOT Phase 1b dose-escalation trial is ongoing and, subject to additional funding, we expect HOT to enter Phase 2 trials in the third quarter of 2013 as a monotherapy for solid tumors with significant unmet medical need.  CLR1502 (GLOW2) is a preclinical, cancer-targeted, non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging.  Together, we believe our compounds are able to "find, treat and follow" cancer anywhere in the body in a novel, effective and highly selective way.  For additional information please visit www.novelos.com

INVESTOR CONTACTS
J. Patrick Genn , Vice President of IR, Novelos Therapeutics, Inc., Madison, Wisc. & Boston, Mass., Ph: (858) 775-7456, Email: jpgenn@novelos.com

Anne Marie Fields , Senior Vice President, LHA, Ph: (212) 838-3777, Email: afields@lhai.com, @LHA_IR_PR

This news release contains forward-looking statements.  You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates.  Such statements are valid only as of today, and we disclaim any obligation to update this information.  These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made.  These statements are based on our current beliefs and expectations as to such future outcomes.  Drug discovery and development involve a high degree of risk.  Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our  pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement.


'/>"/>
SOURCE Novelos Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
2. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
3. Novelos Therapeutics Prices $5.4 Million Public Offering
4. Novelos Therapeutics to Present at LHA Life Sciences & Medical Technologies Virtual Conference on June 28
5. Novelos Therapeutics to Present at Rodman & Renshaw 14th Annual Healthcare Conference on September 11
6. Novelos Therapeutics And Academic Collaborators Present Three Posters At 2012 World Molecular Imaging Congress
7. Novelos Therapeutics Successfully Completes Second Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
8. Novelos Therapeutics Announces Enrollment of First Patient in Solid Tumor Imaging Trial with I-124-CLR1404 (LIGHT) Cancer-targeted PET Imaging Agent at UW Carbone Cancer Center
9. Novelos Therapeutics Closes $2 Million Private Placement
10. Novelos Therapeutics To Present At The Benchmark 2012 Micro Cap Discovery Investor Conference On November 29
11. Novelos Therapeutics Presents Diapeutic Technology Platform At EMIT: Targeted Radiotherapy International Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2020)... BRUNSWICK, N.J. (PRWEB) , ... January 22, 2020 , ... ... Patent (US 10,500,240) on Terminalia chebula. This newly granted patent expands Natreon’s strong patent ... trials. , The primary claim in this patent is, “a method of treating ...
(Date:1/12/2020)... ... 2020 , ... FutuRx, Israel’s leading biopharmaceutical incubator, a partnership ... Inc, operating under a tender from the Israeli Innovation Authority (IIA) has recently ... Tel-Aviv University and Glasgow University. , Epeius pharma develops next generation biological ...
(Date:1/10/2020)... ... 10, 2020 , ... Mymee, a digital care program aimed at solving the ... new website features real client success stories, a simplified description of how the ... self-insured employers and payers. , “There were two key drivers in reimagining the ...
Breaking Medicine Technology:
(Date:1/23/2020)... ... January 23, 2020 , ... ... memory impairment, has announced the Best Memory Care Facilities in Pensacola, Florida. The ... features and amenities. , According to the Alzheimer’s Association , 5.6 ...
(Date:1/23/2020)... ... January 23, 2020 , ... FEI Behavioral Health, a ... workforce resilience, is presenting at the NATSAP 2020 Conference. , NATSAP, The National ... organizations that devote themselves to society’s need for the effective care and education ...
(Date:1/23/2020)... (PRWEB) , ... January 23, 2020 , ... Dr. Dan ... to become a new member of their professional dental staff. The Dentist ... general dentistry, cosmetic dentistry, emergency dentistry and restorative dentistry, all in a ...
(Date:1/23/2020)... ... January 23, 2020 , ... ... SaaS vendor announced their partner agreement with Healthpac, a trusted medical billing ... offices and medical offices an expanded offering. Healthpac’s customers can now access ...
(Date:1/23/2020)... ... January 23, 2020 , ... The Incentive Research Foundation is ... Trustees. Representing all segments of the incentives, rewards, and recognition industry, the IRF ... and providing education highlighting the power of incentive and motivational programs. The Board ...
Breaking Medicine News(10 mins):